CDA | Evidence Driven
CDA | Evidence Driven

Xalkori for Advanced Non-Small Cell Lung Cancer

Details

Files
Generic Name:
Crizotinib
Project Status:
Complete
Therapeutic Area:
Advanced Non-Small Cell Lung Cancer
Manufacturer:
Pfizer Canada Inc.
Brand Name:
Xalkori
Project Line:
Reimbursement Review
Project Number:
PC0008-000
Performance Metric:
N/A — Predated performance metrics
Strength:
200mg and 250mg
Tumour Type:
Lung
Indications:
Advanced Non-Small Cell Lung Cancer
Funding Request:
Patients with anaplastic lymphoma kinase-(ALK) positive advanced non-small cell lung cancer (NSCLC).
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Pfizer Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
pERC Meeting:
Final Recommendation Issued:

The manufacturer, Pfizer Canada Inc. has resubmitted to pCODR for Crizotinib (Xalkori) Advanced NSCLC. Please see the Crizotinib (Xalkori) for Advanced NSCLC Resubmission Details page for more information.

Files

Crizotinib (Xalkori) for Advanced NSCLC - pERC Final Recommendation Final Recommendation October 4, 2012 View PDF
Crizotinib (Xalkori) for Advanced NSCLC - Final Clinical Guidance Report Guidance Reports October 4, 2012 View PDF
Crizotinib (Xalkori) for Advanced NSCLC - Final Economic Guidance Report Guidance Reports October 4, 2012 View PDF
Crizotinib (Xalkori) for Advanced NSCLC - pERC Initial Recommendation Initial Recommendation August 2, 2012 View PDF
Crizotinib (Xalkori) for Advanced NSCLC - PAG Feedback on Initial Recommendation Feedback October 4, 2012 View PDF
Crizotinib (Xalkori) for Advanced NSCLC - Manufacturer (Pfizer) Feedback on Initial Recommendation Feedback October 4, 2012 View PDF
Crizotinib (Xalkori) for Advanced NSCLC - Patient Advocacy Group (LCC) Feedback on Initial Recommendation Feedback October 4, 2012 View PDF
Crizotinib (Xalkori) for Advanced NSCLC - Patient Advocacy Group (LCC) COI Declarations Feedback October 4, 2012 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : October 22, 2012